Baiming Xinkang Biotechnology

About Baiming Xinkang Biotechnology

Worg Pharma is a clinical-stage biopharmaceutical startup that focuses on the development of new treatments for allergic and autoimmune diseases. The company aims to expand its portfolio to other areas of medicine where there is a high demand for treatment options and significant commercial potential.

The company operates in the global pharmaceutical market, with a significant presence in both Europe and China, thanks to its headquarters in Shanghai and a subsidiary in Basel. This strategic positioning allows Worg to tap into the vast resources and opportunities available in these two major pharmaceutical hubs.

Worg's business model revolves around the development of a pipeline for immunotherapy treatments. This involves creating new drugs internally and partnering with other companies externally. The company's flexible approach allows it to adapt to the changing needs and opportunities in the pharmaceutical industry.

Worg's primary revenue stream comes from the commercialization of its drugs. Once a drug is developed and approved for use, it is sold to healthcare providers who then prescribe it to patients. The company's leadership team, comprised of international executives from China, the United States, and Europe, brings a wealth of experience in life science, pharmaceutical development, regulatory affairs, and commercialization, which positions the company well for success in this highly competitive market.